Brad Loncar's Biotech Takeaways

<p>Brad Loncar weighs in on Eli Lilly's (LLY) experimental Alzheimer's drug meeting primary endpoint of a small trial study. Also, the biggest deal at the JPM Conference was Beigene (BGNE) licensing a PD-1 cancer drug Tislelizumab.</p>